INT11066

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 1992
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 7
Disease Relevance 0.89
Pain Relevance 0.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (NPR1)
Anatomy Link Frequency
chondrocytes 1
platelet 1
NPR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Enkephalin 1 100.00 Very High Very High Very High
tolerance 5 99.24 Very High Very High Very High
Osteoarthritis 105 97.38 Very High Very High Very High
Angina 4 80.08 Quite High
metalloproteinase 3 79.16 Quite High
tetrodotoxin 1 76.80 Quite High
Action potential 4 69.68 Quite High
Pain 4 52.40 Quite High
adenocard 1 49.72 Quite Low
Potency 1 29.92 Quite Low
Disease Link Frequency Relevance Heat
Natriuresis 1 100.00 Very High Very High Very High
Leukemia 1 97.80 Very High Very High Very High
Osteoarthritis 108 97.38 Very High Very High Very High
Cv General 3 Under Development 4 80.08 Quite High
Fracture Healing 1 60.72 Quite High
Apoptosis 42 55.32 Quite High
Arthralgia 1 52.40 Quite High
Stress 9 5.92 Low Low
Death 12 5.00 Very Low Very Low Very Low
Rheumatoid Arthritis 9 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An inhibitor of guanylate cyclase (LY83583) blocked the PEF-stimulated increase in cGMP and DNA content.
Negative_regulation (inhibitor) of guanylate cyclase
1) Confidence 0.27 Published 2008 Journal J. Orthop. Res. Section Abstract Doc Link 18240331 Disease Relevance 0.11 Pain Relevance 0.05
This phenomenon is not associated either with cross tolerance to sodium nitroprusside or with down-regulation of platelet guanylate cyclase.
Negative_regulation (regulation) of platelet guanylate cyclase in platelet associated with tolerance
2) Confidence 0.26 Published 1997 Journal Am. J. Cardiol. Section Abstract Doc Link 9230146 Disease Relevance 0.23 Pain Relevance 0.37
Interestingly, the most potent inhibitor of MMP-1 and MMP-13 production was LY83583, an inhibitor of NO-dependent soluble guanylate cyclase and of cGMP.
Negative_regulation (inhibitor) of guanylate cyclase
3) Confidence 0.11 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.11 Pain Relevance 0
This enzyme is involved in the inactivation of regulatory peptides such as enkephalins and atrial natriuretic peptide and its expression on the cell surface is therefore essential.
Negative_regulation (inactivation) of atrial natriuretic peptide associated with natriuresis and enkephalin
4) Confidence 0.09 Published 1992 Journal Biochem. Pharmacol. Section Abstract Doc Link 1533518 Disease Relevance 0.20 Pain Relevance 0.10
To examine the effects of ET-1 on NO production, a dose–response curve was performed by incubating OA chondrocytes for 24 hours with increased concentrations (0–100 nM) of ET-1, or by pretreating with protein kinase inhibitors or a guanylate cyclase inhibitor and ET-1 as already described.
Negative_regulation (inhibitor) of guanylate cyclase in chondrocytes associated with osteoarthritis
5) Confidence 0.08 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.23 Pain Relevance 0.11
The effect of ET-1, protein kinase inhibitors and a guanylate cyclase inhibitor (LY83583) on MMP-1, MMP-13 and NO production
Negative_regulation (inhibitor) of guanylate cyclase
6) Confidence 0.08 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0 Pain Relevance 0.04
The hypericin-induced APD lengthening recorded in the Ringer Sr2+ was prevented by blocking soluble guanylate cyclase (sGC) activity by 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (13 microM), which mimicked the effects of hypericin.
Negative_regulation (blocking) of cyclase
7) Confidence 0.00 Published 2007 Journal J. Nat. Prod. Section Abstract Doc Link 17291039 Disease Relevance 0 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox